脈絡膜新生血管の世界市場レポート 2025年

脈絡膜新生血管市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.7%で56億4,000万米ドルに成長する見込みです。予測期間中の成長は、患者意識の高まり、光コヒーレンストモグラフィ血管造影の採用拡大、低侵襲手技の需要増加、有利な償還政策、老人人口の増加などの要因によるものです。この時期の主な動向には、硝子体内抗血管内皮増殖因子（VEGF）療法の出現、新しい遺伝子治療、遺伝子治療アプローチ、遠隔医療の採用、併用療法の開発、個別化治療戦略などがあります。

加齢黄斑変性症（AMD）の有病率の増加が、今後の脈絡膜新生血管（CNV）市場の成長を牽引すると予想されています。AMDは、黄斑部が徐々に損傷し、特に高齢者の中心視力が低下する眼の疾患です。AMDの有病率の上昇は、人口の高齢化、平均寿命の延長、ライフスタイルの変化、遺伝的影響、環境リスクへの曝露の増加などの要因によるものです。CNVは、網膜の下で血管が異常に増殖して視力が低下する湿性AMDにおいて重要な役割を果たしています。CNVを管理し、AMDの進行を遅らせ、罹患者の中心視力を維持するために、抗VEGF療法などの先進治療が行われています。例えば、2022年9月、米国国立衛生研究所は、2040年までにAMD患者が3億人に達し、2050年までに540万人の米国人が罹患する可能性があると予測しました。したがって、AMDの有病率の上昇がCNV市場の成長を促進しています。

CNV市場の主要企業は、光線力学的療法（PDT）のような革新的な治療法の開発に注力しており、眼科医療専門家に患者の転帰と治療効果を高める、より正確で効果的な選択肢を提供しています。PDTは、光によって活性化される光増感剤を使用して、異常細胞やがん細胞を標的にして破壊します。例えば、2023年2月、カナダを拠点とするヘルスケア企業ボシュロムとフィンランドを拠点とするバイオメディカル企業Modulight社は、米国食品医薬品局から光線力学的レーザーML6710iが承認されたことを発表しました。この治療法は、ボシュロムのVISUDYNE療法と併用され、AMDによるCNVを治療します。この先進的な移動式眼科用レーザーは、眼内の異常な血管を治療するための標的を絞ったアプローチを提供し、病気のさらなる進行を防ぎ、視力を維持するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界脈絡膜新生血管PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の脈絡膜新生血管市場：成長率分析
• 世界の脈絡膜新生血管市場の実績：規模と成長, 2019-2024
• 世界の脈絡膜新生血管市場の予測：規模と成長, 2024-2029, 2034F
• 世界脈絡膜新生血管総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脈絡膜新生血管市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血管新生療法
• レーザー光凝固術
• 光線力学療法
• ベルテポルフィンナトリウム
• ラニビズマブ
• ベバシズマブ
• アフリベルセプト
• ペガプタニブナトリウム
• 世界の脈絡膜新生血管市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 加齢黄斑変性症（AMD）
• 糖尿病黄斑浮腫（DME）
• 中心性漿液性脈絡網膜症（CSC）
• ポリープ状脈絡膜血管症（PCV）
• 近視性黄斑変性症（MMD）
• その他の適応症
• 世界の脈絡膜新生血管市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硝子体内
• 結膜下
• 眼周囲
• オーラル
• 世界の脈絡膜新生血管市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 眼科クリニック
• 外来手術センター
• 研究センター
• 世界の脈絡膜新生血管市場抗血管新生療法（抗VEGF療法）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ラニビズマブ
• ベバシズマブ
• アフリベルセプト
• ペガプタニブナトリウム
• 世界の脈絡膜新生血管市場レーザー光凝固術の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 熱レーザー光凝固術
• マイクロパルスレーザー療法
• 世界の脈絡膜新生血管市場光線力学療法（PDT）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準PDT
• 低線量PDT
• 半量PDT
• 世界の脈絡膜新生血管市場ベルテポルフィンナトリウムの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内投与
• 抗VEGFとの併用療法
• 世界の脈絡膜新生血管市場ラニビズマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 月1回投与
• 必要に応じて投与
• 治療と延長のレジメン
• 世界の脈絡膜新生血管市場ベバシズマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応外使用
• 複合硝子体内注射
• 世界の脈絡膜新生血管市場アフリベルセプトの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 固定投与レジメン
• 治療と延長のレジメン
• 世界の脈絡膜新生血管市場ペガプタニブナトリウムの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤療法
• 併用療法

第7章 地域別・国別分析

• 世界の脈絡膜新生血管市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の脈絡膜新生血管市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脈絡膜新生血管市場：競合情勢
• 脈絡膜新生血管市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• Alcon Inc.
• Genentech Inc.
• Bausch+Lomb Incorporated
• Samsung Bioepis Co. Ltd.
• Santen Pharmaceutical Co. Ltd.
• Apellis Pharmaceuticals Inc.
• Kodiak Sciences Inc.
• Xbrane Biopharma AB
• Allergan Inc.
• Adverum Biotechnologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脈絡膜新生血管市場2029：新たな機会を提供する国
• 脈絡膜新生血管市場2029：新たな機会を提供するセグメント
• 脈絡膜新生血管市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Choroidal neovascularization (CNV) is the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These newly formed blood vessels are fragile and prone to leaking fluid or blood, which can damage retinal tissues and lead to vision distortion or loss.

The main treatment options for choroidal neovascularization include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent the growth of abnormal blood vessels. These treatments are commonly used for specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related conditions. The administration route may vary, including intravitreal, subconjunctival, periocular, or oral methods. These therapies are primarily administered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

The choroidal neovascularization market research report is one of a series of new reports from The Business Research Company that provides choroidal neovascularization market statistics, including the choroidal neovascularization industry global market size, regional shares, competitors with the choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends, and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of sedentary lifestyle diseases, the rising incidence of age-related macular degeneration, a higher occurrence of retinal illnesses, a growing elderly population, escalating eye care costs, and expanding education and screening initiatives.

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period can be attributed to factors such as increasing patient awareness, the growing adoption of optical coherence tomography angiography, rising demand for minimally invasive procedures, favorable reimbursement policies, and a growing geriatric population. Key trends in this period include the emergence of intravitreal anti-vascular endothelial growth factor (VEGF) therapies, new gene treatments, gene therapy approaches, the adoption of telemedicine, the development of combination therapies, and personalized treatment strategies.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive the growth of the choroidal neovascularization (CNV) market in the future. AMD is an eye condition that gradually damages the macula, resulting in central vision loss, particularly among older adults. The rising prevalence of AMD is attributed to factors such as an aging population, increased life expectancy, lifestyle changes, genetic influences, and increased exposure to environmental risks. CNV plays a significant role in wet AMD, where abnormal blood vessel growth beneath the retina leads to vision deterioration. Advanced treatments such as anti-VEGF therapy are used to manage CNV, slow the progression of AMD, and help preserve central vision in affected individuals. For example, in September 2022, the National Institutes of Health projected that by 2040, AMD cases may reach 300 million, and by 2050, 5.4 million Americans could be affected. Therefore, the rising prevalence of AMD is driving the growth of the CNV market.

Leading companies in the CNV market are focusing on developing innovative treatments, such as photodynamic therapy (PDT), to provide eye care professionals with more precise and effective options that enhance patient outcomes and treatment delivery. PDT uses a photosensitizing agent activated by light to target and destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the approval of the ML6710i photodynamic laser by the U.S. Food and Drug Administration. This therapy is used in conjunction with Bausch + Lomb's VISUDYNE therapy to treat CNV caused by AMD. The advanced, mobile ophthalmic laser offers a targeted approach to treating abnormal blood vessels in the eye, helping to prevent further disease progression and preserve vision.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. With this acquisition, Sandoz aims to expand its portfolio in the ophthalmic sector, strengthening its ability to offer innovative treatments for retinal diseases, such as AMD. Coherus BioSciences, a U.S.-based biopharmaceutical company, focuses on the research and development of treatments for diseases such as CNV.

Major players in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in choroidal neovascularization report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Choroidal Neovascularization Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on choroidal neovascularization market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for choroidal neovascularization ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The choroidal neovascularization market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
• 3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
• 4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers
• Subsegments:
• 1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
• 2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
• 3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
• 4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
• 5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
• 6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
• 7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
• 8) By Pegaptanib Sodium: Monotherapy; Combination Therapy
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; Bayer Aktiengesellschaft; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Choroidal Neovascularization Market Characteristics

3. Choroidal Neovascularization Market Trends And Strategies

4. Choroidal Neovascularization Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Choroidal Neovascularization Growth Analysis And Strategic Analysis Framework

• 5.1. Global Choroidal Neovascularization PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Choroidal Neovascularization Market Growth Rate Analysis
• 5.4. Global Choroidal Neovascularization Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Choroidal Neovascularization Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Choroidal Neovascularization Total Addressable Market (TAM)

6. Choroidal Neovascularization Market Segmentation

• 6.1. Global Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Angiogenic Therapy
• Laser Photocoagulation
• Photodynamic Therapy
• Verteporfin Sodium
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.2. Global Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Age-Related Macular Degeneration (AMD)
• Diabetic Macular Edema (DME)
• Central Serous Chorioretinopathy (CSC)
• Polypoidal Choroidal Vasculopathy (PCV)
• Myopic Macular Degeneration (MMD)
• Other Indications
• 6.3. Global Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravitreal
• Subconjunctival
• Periocular
• Oral
• 6.4. Global Choroidal Neovascularization Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Research Centers
• 6.5. Global Choroidal Neovascularization Market, Sub-Segmentation Of Anti-Angiogenic Therapy (Anti-VEGF Therapy), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ranibizumab
• Bevacizumab
• Aflibercept
• Pegaptanib Sodium
• 6.6. Global Choroidal Neovascularization Market, Sub-Segmentation Of Laser Photocoagulation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thermal Laser Photocoagulation
• MicroPulse Laser Therapy
• 6.7. Global Choroidal Neovascularization Market, Sub-Segmentation Of Photodynamic Therapy (PDT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard PDT
• Low-Fluence PDT
• Half-Dose PDT
• 6.8. Global Choroidal Neovascularization Market, Sub-Segmentation Of Verteporfin Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Administration
• Combination Therapy With Anti-VEGF
• 6.9. Global Choroidal Neovascularization Market, Sub-Segmentation Of Ranibizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monthly Dosing
• As-Needed Dosing
• Treat-and-Extend Regimen
• 6.10. Global Choroidal Neovascularization Market, Sub-Segmentation Of Bevacizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Off-Label Use
• Compounded Intravitreal Injections
• 6.11. Global Choroidal Neovascularization Market, Sub-Segmentation Of Aflibercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fixed-Dosing Regimen
• Treat-and-Extend Regimen
• 6.12. Global Choroidal Neovascularization Market, Sub-Segmentation Of Pegaptanib Sodium, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy

7. Choroidal Neovascularization Market Regional And Country Analysis

• 7.1. Global Choroidal Neovascularization Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Choroidal Neovascularization Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Choroidal Neovascularization Market

• 8.1. Asia-Pacific Choroidal Neovascularization Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Choroidal Neovascularization Market

• 9.1. China Choroidal Neovascularization Market Overview
• 9.2. China Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Choroidal Neovascularization Market

• 10.1. India Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Choroidal Neovascularization Market

• 11.1. Japan Choroidal Neovascularization Market Overview
• 11.2. Japan Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Choroidal Neovascularization Market

• 12.1. Australia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Choroidal Neovascularization Market

• 13.1. Indonesia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Choroidal Neovascularization Market

• 14.1. South Korea Choroidal Neovascularization Market Overview
• 14.2. South Korea Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Choroidal Neovascularization Market

• 15.1. Western Europe Choroidal Neovascularization Market Overview
• 15.2. Western Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Choroidal Neovascularization Market

• 16.1. UK Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Choroidal Neovascularization Market

• 17.1. Germany Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Choroidal Neovascularization Market

• 18.1. France Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Choroidal Neovascularization Market

• 19.1. Italy Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Choroidal Neovascularization Market

• 20.1. Spain Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Choroidal Neovascularization Market

• 21.1. Eastern Europe Choroidal Neovascularization Market Overview
• 21.2. Eastern Europe Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Choroidal Neovascularization Market

• 22.1. Russia Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Choroidal Neovascularization Market

• 23.1. North America Choroidal Neovascularization Market Overview
• 23.2. North America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Choroidal Neovascularization Market

• 24.1. USA Choroidal Neovascularization Market Overview
• 24.2. USA Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Choroidal Neovascularization Market

• 25.1. Canada Choroidal Neovascularization Market Overview
• 25.2. Canada Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Choroidal Neovascularization Market

• 26.1. South America Choroidal Neovascularization Market Overview
• 26.2. South America Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Choroidal Neovascularization Market

• 27.1. Brazil Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Choroidal Neovascularization Market

• 28.1. Middle East Choroidal Neovascularization Market Overview
• 28.2. Middle East Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Choroidal Neovascularization Market

• 29.1. Africa Choroidal Neovascularization Market Overview
• 29.2. Africa Choroidal Neovascularization Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Choroidal Neovascularization Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Choroidal Neovascularization Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Choroidal Neovascularization Market Competitive Landscape And Company Profiles

• 30.1. Choroidal Neovascularization Market Competitive Landscape
• 30.2. Choroidal Neovascularization Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Choroidal Neovascularization Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Limited
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. Astellas Pharma Inc.
• 31.4. Biogen Inc.
• 31.5. Chugai Pharmaceutical Co. Ltd.
• 31.6. Alcon Inc.
• 31.7. Genentech Inc.
• 31.8. Bausch + Lomb Incorporated
• 31.9. Samsung Bioepis Co. Ltd.
• 31.10. Santen Pharmaceutical Co. Ltd.
• 31.11. Apellis Pharmaceuticals Inc.
• 31.12. Kodiak Sciences Inc.
• 31.13. Xbrane Biopharma AB
• 31.14. Allergan Inc.
• 31.15. Adverum Biotechnologies Inc.

32. Global Choroidal Neovascularization Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Choroidal Neovascularization Market

34. Recent Developments In The Choroidal Neovascularization Market

35. Choroidal Neovascularization Market High Potential Countries, Segments and Strategies

• 35.1 Choroidal Neovascularization Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Choroidal Neovascularization Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Choroidal Neovascularization Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer